I would have thought additional analysis of the Phase 2 trial data would allow them to identify higher probability responder groups. Part of phase 3 trial design is to establish the IFU to ensure success. Of course that is a 2 edge sword in that if you make it too specific you exclude a large potential patient population from being treated. I note that in OPT documentation, they claim that half the patients using current medications do not achieve meaningful clinical outcomes. Imagine, if potential non responders could be tested and filtered out before being treated - there goes half the income! I'm sure no one is looking too close into establishing this criteria, atm
But anyway, getting back to OPT-302, if we can learn anything from the numerous Sirtex trial failures, we would want to ensure we have recorded enough characteristics in the trial design to allow for a potential second chance approval on a smaller subset of responding patients. Hopefully, the second chance card won't need to be used, but at least we don't get a total wipe out and have to do another trial.
- Forums
- ASX - By Stock
- OPT
- price target
price target, page-44
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.0¢ |
Change
-0.005(1.20%) |
Mkt cap ! $504.7M |
Open | High | Low | Value | Volume |
42.0¢ | 42.5¢ | 40.8¢ | $499.8K | 1.198M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 24187 | 41.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 20978 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 54000 | 0.405 |
16 | 220452 | 0.400 |
3 | 11299 | 0.395 |
6 | 55440 | 0.390 |
1 | 9090 | 0.385 |
Price($) | Vol. | No. |
---|---|---|
0.425 | 14457 | 1 |
0.430 | 219473 | 2 |
0.440 | 25270 | 2 |
0.445 | 30000 | 2 |
0.450 | 60000 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |